CN114340671A - 对gpc3特异性的抗体及其使用方法 - Google Patents

对gpc3特异性的抗体及其使用方法 Download PDF

Info

Publication number
CN114340671A
CN114340671A CN202080062015.4A CN202080062015A CN114340671A CN 114340671 A CN114340671 A CN 114340671A CN 202080062015 A CN202080062015 A CN 202080062015A CN 114340671 A CN114340671 A CN 114340671A
Authority
CN
China
Prior art keywords
antibody
amino acid
acid sequence
ser
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080062015.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·拉布卡
P·M·德雷克
Y·C·金
R·M·巴菲尔德
M·保宗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RP Scherer Technologies LLC
Original Assignee
RP Scherer Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RP Scherer Technologies LLC filed Critical RP Scherer Technologies LLC
Publication of CN114340671A publication Critical patent/CN114340671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080062015.4A 2019-08-01 2020-07-31 对gpc3特异性的抗体及其使用方法 Pending CN114340671A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881547P 2019-08-01 2019-08-01
US62/881,547 2019-08-01
PCT/US2020/044515 WO2021022166A1 (en) 2019-08-01 2020-07-31 Antibody specific for gpc3 and methods of use thereof

Publications (1)

Publication Number Publication Date
CN114340671A true CN114340671A (zh) 2022-04-12

Family

ID=74228511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062015.4A Pending CN114340671A (zh) 2019-08-01 2020-07-31 对gpc3特异性的抗体及其使用方法

Country Status (8)

Country Link
US (1) US12595314B2 (https=)
EP (1) EP4007604A4 (https=)
JP (1) JP7828272B2 (https=)
KR (1) KR20220083665A (https=)
CN (1) CN114340671A (https=)
AU (1) AU2020319874A1 (https=)
CA (1) CA3148807A1 (https=)
WO (1) WO2021022166A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118488970A (zh) * 2021-10-15 2024-08-13 乐普创一生物科技（上海）有限公司 抗磷脂酰肌醇蛋白聚糖3抗体
WO2025023650A1 (ko) * 2023-07-21 2025-01-30 한국생명공학연구원 신규한 항-gpc3 키메릭 항원 수용체 및 이를 발현하는 면역세포

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145469A1 (en) * 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US20150259417A1 (en) * 2004-07-09 2015-09-17 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican 3 Antibody
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
WO2017074074A1 (en) * 2015-10-29 2017-05-04 Mogam Institute For Biomedical Research Novel anti-glypican 3 antibody and pharmaceutical composition containing the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
AU2002330482A1 (en) 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) * 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2009120611A2 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150259417A1 (en) * 2004-07-09 2015-09-17 Chugai Seiyaku Kabushiki Kaisha Anti-Glypican 3 Antibody
WO2012145469A1 (en) * 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
WO2017074074A1 (en) * 2015-10-29 2017-05-04 Mogam Institute For Biomedical Research Novel anti-glypican 3 antibody and pharmaceutical composition containing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MINGQIAN FENG 等: "Glypican-3 antibodies: A new therapeutic target for liver cancer", FEBS LETTERS, vol. 588, 15 October 2013 (2013-10-15), pages 377 - 382, XP028669969, DOI: 10.1016/j.febslet.2013.10.002 *
XIAOLONG TANG 等: "Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma", DRUG DELIVERY, 19 June 2018 (2018-06-19), pages 1484 - 1494, XP055791331, DOI: 10.1080/10717544.2018.1477859 *

Also Published As

Publication number Publication date
JP2022544068A (ja) 2022-10-17
WO2021022166A1 (en) 2021-02-04
CA3148807A1 (en) 2021-02-04
JP7828272B2 (ja) 2026-03-11
US12595314B2 (en) 2026-04-07
AU2020319874A1 (en) 2022-03-17
KR20220083665A (ko) 2022-06-20
US20220251237A1 (en) 2022-08-11
EP4007604A1 (en) 2022-06-08
EP4007604A4 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
JP6578206B2 (ja) Ｃｄ２２に特異的な抗体およびその使用方法
EP4299589A1 (en) Anti-human cd73 antibody and use thereof
US20230002503A1 (en) Nano-antibody targeting caix antigen and application thereof
US20250084182A1 (en) Antibody specific for mucin-1 and methods of use thereof
CN113045659B (zh) 抗cd73人源化抗体
CN114340671A (zh) 对gpc3特异性的抗体及其使用方法
US20260008852A1 (en) Anti-B7-H3 Antibody and Methods of Use Thereof
CN113461821B (zh) 抗cd3人源化抗体
US20240360216A1 (en) Anti-cd3 humanized antibody
JP7768902B2 (ja) Ａｂｃｇ２排出ポンプ－がん抗原多重特異性抗体並びにそれらに関連する組成物、試薬、キット、及び方法
CN116157418A (zh) 抗tigit抗体及其使用方法
CN118324916B (zh) 一种抗人gprc5d的单克隆抗体及其制备方法和用途
CN117430708A (zh) 一种抗Claudin18.2抗体
CN118043328A (zh) 对nectin-4特异性的抗体和抗体缀合物及其使用方法
EA052100B1 (ru) Антитело, специфичное в отношении муцина-1, и способы его применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination